The vitamin D MS Prevention Trial – PrevANZ is a world-first clinical trial that will test whether vitamin D supplementation can prevent MS in those at risk of developing the disease.
This is a Phase IIb placebo-controlled, randomised trial – this is a phase in the clinical trials pipeline that looks at both safety and efficacy as well as identifying the most appropriate dose. The trial aims to identify whether, and at what dose, vitamin D supplements can prevent multiple sclerosis in people with a first episode of symptoms that may be a precursor to MS (known as clinically isolated syndrome or CIS). This might include symptoms such as blurred vision (optic neuritis) or limb weakness (transverse myelitis) (these symptoms may also be described as a first demyelinating event).
The need for the vitamin D MS prevention trial has arisen from a now significant body of evidence for the role that vitamin D deficiency plays in MS. However, to date there has not been a clinical trial conducted to provide the necessary evidence on the benefits that can be expected from vitamin D supplementation or the optimal dose.
MS Research Australia and colleagues in the MS research community see this trial as a high priority and an area in which the expertise in Australia and New Zealand can contribute significantly to the prevention and better treatment of MS globally.
A team of clinicians and researchers from Australia and New Zealand, with expertise in MS neurology, MS clinical trials, endocrinology and epidemiology has been assembled to oversee the trial. The Trish Foundation is proud to have made a contribution to PrevANZ.
Recruitment for the trial is ongoing, and the team is excited to have reached 67% of our target enrolment of 240 people. It is expected the trial will be complete in 2019.